Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real World Study on the Efficacy and Safety of Agomelatin Combined With Second Generation Antipsychotics in the Treatment of Negative Symptoms in Patients With Schizophrenia

NCT05646264 is registered in ClinicalTrials.gov with Shanghai Mental Health Center as lead sponsor.

NCT NCT05646264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05646264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real World Study on the Efficacy and Safety of Agomelatin Combined With Second Generation Antipsychotics in the Treatment of Negative Symptoms in Patients With Schizophrenia
Lead sponsor
Shanghai Mental Health Center
Phase
Phase 4
Overall status
Unknown status
Start date
January 1, 2023
Completion date
August 1, 2023
Enrollment
220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

negative symptoms in schizophrenia, schizophrenia